Ovid Therapeutics Inc.Company Review & Valuation

OVID
Nasdaq
Latest Price
5.75USD
Market Capitalization
274.94mUSD

About Ovid Therapeutics Inc.

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I cShow morelinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate that is in Phase Ib/IIa trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the clinical setting. The company has collaboration agreement with Takeda Pharmaceutical Company Limited. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.Show less

Industry
Biotechnology
HQ Location
New York, New York

Stock Price

Price data not available for Ovid Therapeutics Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

NovaBay Pharmaceuticals
Apricus Biosciences
Trevena
Ovoca Bio

back to top